Novo Nordisk (NVO) announced on Friday that it has secured a legal victory against compounders selling unauthorized versions ...

Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final ...

Big compounders will have until May 22 to stop producing and dispensing compounded semaglutide, while smaller, state-run ...

A federal judge rejected a bid by compounding pharmacies to continue selling versions of weight-loss drug Wegovy and diabetes ...

The ruling means that small-scale compounders must immediately stop making their versions of Novo’s Ozempic and Wegovy, while ...

The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...

Hims & Hers (HIMS) stock in focus as a U.S. court denies injunction to continue making cheap versions of Novo Nordisk's (NVO) ...

Harvard Medical School experts reported that a rapid loss of fat in the face can cause a hollowed look to the face; changes ...

Eli Lilly suit against Houston’s Empower Pharmacy is a battle over access to a multi-billion dollar market for weight loss ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

A US judge has rejected efforts by a compounded drugs industry group to keep making an alternative version of Novo Nordisk’s popular drug semaglutide, opening the door for the US Food and Drug ...